
    
      1. Primary Objectives Safety run-in - To determine the safety of SABR for the treatment of
           primary lung disease and N1 (hilar) node in stage T1-2a N1 NSCLC Phase II - To determine
           2-year local control of SABR for T1-2a N1 NSCLC with sequential chemotherapy

        2. Secondary Objectives Phase II - To determine overall and progression-free survival
           times, pattern of failures, and rates of â‰¥ grade 3 adverse events after SABR for T1-2a
           N1 NSCLC combined with sequential chemotherapy
    
  